Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric CKD anemia maintenance study of subcutaneous Mircera starting dose
2016-004779-39Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Epoetin alfa RB in Uraemic Anaemia, sponsored by Roche. Primary endpoint: Change in hemoglobin concentration. Started Dec 2017; status: completed.
02
Drugs
Epoetin alfa RB
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on 2016-004779-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004779-39.